Skip to contentW
West Pharmaceutical Services Inc
W
WSTWest Pharmaceutical Services Inc Q1 2024 · 10-Q
Revenue$695.40M$695.40M−3.0% vs Q1 2023 Net Income$115.30M$115.30M−17.6% vs Q1 2023 EPS Diluted$1.55$1.55−16.2% vs Q1 2023 Gross Profit$230,200,000−15.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
West Pharmaceutical Services Inc · CIK 105770 · Engraved from SEC EDGAR
Operating Cash Flow$118,200,000−14.4% Free Cash Flowderived$27,600,000−50.7% Margins · derivedGross margin33.1%−4.8 pt vs Q1 2023
Operating margin17.7%−4.0 pt vs Q1 2023
Net margin16.6%−3.0 pt vs Q1 2023
ended Mar 31, 2024 · filed Apr 25, 2024 · 25 d after period end